LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | PD0325901 | 10.0 | uM | LJP5 | 72 | hr | 1097 | 1841 | 3769 | 0.4884 | 0.2783 |
BT-20 | PD0325901 | 10.0 | uM | LJP6 | 72 | hr | 1097 | 2178 | 3769 | 0.5778 | 0.4044 |
BT-20 | PD173074 | 10.0 | uM | LJP6 | 72 | hr | 1097 | 3261 | 3769 | 0.8652 | 0.8098 |
BT-20 | PD184352 | 10.0 | uM | LJP5 | 72 | hr | 1097 | 1974 | 3769 | 0.5239 | 0.3283 |
BT-20 | Pelitinib | 10.0 | uM | LJP5 | 72 | hr | 1097 | 807 | 3769 | 0.2143 | -0.1084 |
BT-20 | PF431396 | 10.0 | uM | LJP5 | 72 | hr | 1097 | 780 | 3769 | 0.2070 | -0.1186 |
BT-20 | PF477736 | 10.0 | uM | LJP5 | 72 | hr | 1097 | 1691 | 3769 | 0.4486 | 0.2222 |
BT-20 | PF562271 | 10.0 | uM | LJP6 | 72 | hr | 1097 | 700 | 3769 | 0.1859 | -0.1484 |
BT-20 | PHA-665752 | 10.0 | uM | LJP5 | 72 | hr | 1097 | 796 | 3769 | 0.2113 | -0.1125 |
BT-20 | PHA-793887 | 10.0 | uM | LJP6 | 72 | hr | 1097 | 740 | 3769 | 0.1964 | -0.1336 |
BT-20 | PI103 | 10.0 | uM | LJP6 | 72 | hr | 1097 | 888 | 3769 | 0.2357 | -0.0782 |
BT-20 | PLX-4720 | 10.0 | uM | LJP5 | 72 | hr | 1097 | 1979 | 3769 | 0.5250 | 0.3300 |
BT-20 | QL-X-138 | 10.0 | uM | LJP6 | 72 | hr | 1097 | 675 | 3769 | 0.1791 | -0.1580 |
BT-20 | QL-XII-47 | 10.0 | uM | LJP6 | 72 | hr | 1097 | 798 | 3769 | 0.2118 | -0.1119 |
BT-20 | Radicicol | 10.0 | uM | LJP5 | 72 | hr | 1097 | 704 | 3769 | 0.1868 | -0.1472 |
BT-20 | Radicicol | 10.0 | uM | LJP6 | 72 | hr | 1097 | 595 | 3769 | 0.1580 | -0.1877 |
BT-20 | Seliciclib | 10.0 | uM | LJP5 | 72 | hr | 1097 | 1639 | 3769 | 0.4349 | 0.2029 |
BT-20 | Ruxolitinib | 10.0 | uM | LJP5 | 72 | hr | 1097 | 3148 | 3769 | 0.8351 | 0.7674 |
BT-20 | XL147 | 10.0 | uM | LJP5 | 72 | hr | 1097 | 1580 | 3769 | 0.4193 | 0.1809 |
BT-20 | Saracatinib | 10.0 | uM | LJP6 | 72 | hr | 1097 | 1674 | 3769 | 0.4443 | 0.2161 |
BT-20 | Selumetinib | 10.0 | uM | LJP6 | 72 | hr | 1097 | 3302 | 3769 | 0.8761 | 0.8252 |
BT-20 | Sirolimus | 10.0 | uM | LJP6 | 72 | hr | 1097 | 2335 | 3769 | 0.6195 | 0.4633 |
BT-20 | Sorafenib | 10.0 | uM | LJP6 | 72 | hr | 1097 | 1328 | 3769 | 0.3523 | 0.0863 |
BT-20 | SU11274 | 10.0 | uM | LJP5 | 72 | hr | 1097 | 1251 | 3769 | 0.3319 | 0.0575 |
BT-20 | Fedratinib | 10.0 | uM | LJP5 | 72 | hr | 1097 | 756 | 3769 | 0.2006 | -0.1276 |